Friday 6 November 2026 Export VRDN’s income statement to Excel — free account

Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.8 million, up 23,359.9% from fiscal 2024.

Revenue: −63.5%
EPS: −5.00%
Free cash flow: −9.92%
Total debt: +1,064.9%

Quarter to September 2026, against a year earlier

Insider buying

29.07 0.52 +1.82%

Follow VRDN

Alert me

Market cap: $3.2B
P/E: 0.0×
Fwd P/E: −6.2×
Dividend yield: —
F-score: 3/9
Altman Z: 6.69
Beneish M: n/a
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Bought, $m 20.00

Sold, $m 0.42

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	1	—	—	—	—	—	—
Sell	1	—	—	—	—	—	—	—	1	—	—	—

Insider Ownership 1.41%

Capital & Financial Ratios $m

Size

Market Cap 3,230.00

Revenue ttm 26.31

Net income ttm (453.58)

Free cash flow ttm (343.44)

Net debt Q (955.20)

Valuation

P/E 0.00

Forward P/E (6.22)

Price / sales 117.81

Forward P/S Powerpack

Price / FCF 0.00

Price / book 5.49

Financial health

Current ratio Q 14.46

Debt / equity Q 0.00

Interest coverage Q (15.20)

Growth

Revenue growth Q −63.51%

Operating income growth Q −158.61%

EPS, this year −7.63%

EPS, next year A +39.99%

Revenue, next year A −65.70%

EPS, past 5 yrs —

EPS, next 5 yrs A +65.86%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 67.44%

10-year low 10-year high

P/B against its own 10 years 90.72%

10-year low 10-year high

EV/Sales against its own 10 years 59.10%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	477	718	875	955
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	0	—	—	—
	486	738	894	1,013

	2023	2024	2025	Q'26
Payables	2	2	9	9
ST’ Debt	—	—	—	—
Other	—	—	—	—
	27	48	71	70

Compound Annual Growth %

	10y	5y	3y
Sales	39.50%	132.18%	241.95%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	52.80%	43.17%	22.27%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −1.01 Actual −0.81

−1.12 −1.03 −0.95 −0.86 −0.77

Q4 FY25 Miss −0.18

Q1 FY26 Beat +0.16

Q2 FY26 Miss −0.08

Q3 FY26 Beat +0.20

Q4 FY26 — Feb 25

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q4 FY25	−0.90	−1.08	Miss by 0.18
Q1 FY26	−1.06	−0.90	Beat by 0.16
Q2 FY26	−0.97	−1.05	Miss by 0.08
Q3 FY26	−1.01	−0.81	Beat by 0.20
Q4 FY26	−0.94	—	Reports 25 February 2027

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.90)	(1.05)	—	—	—
’25	(0.87)	(1.00)	(0.34)	(1.08)	(3.32)
’24	(0.79)	(1.02)	(1.15)	(1.01)	(3.07)
’23	(1.61)	(1.27)	(1.09)	(1.35)	(5.31)
’22	(0.98)	(1.06)	(0.86)	(1.13)	(4.05)
’21	(2.91)	(2.21)	(1.25)	(1.32)	(6.68)
’20	(2.70)	(1.80)	(1.50)	(23.07)	(31.13)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	26	—	—
’25	0	0	71	0	71
’24	0	0	0	0	0
’23	0	0	0	0	0
’22	0	0	1	0	2
’21	1	1	0	0	3
’20	1	0	—	0	1

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(120)	(105)	(93)	—	—
’25	(93)	(75)	(85)	(24)	(276)
’24	(45)	(46)	(68)	(73)	(232)
’23	(62)	(45)	(39)	(38)	(184)
’22	(21)	(18)	(21)	(34)	(94)
’21	(12)	(15)	(12)	(17)	(55)
’20	(8)	(7)	(5)	(9)	(30)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(120)	(107)	(93)	—	—
’25	(93)	(75)	(85)	(24)	(277)
’24	(45)	(46)	(68)	(73)	(233)
’23	(62)	(46)	(39)	(38)	(185)
’22	(21)	(18)	(21)	(34)	(95)
’21	(12)	(15)	(12)	(17)	(55)
’20	(8)	(7)	(5)	(9)	(30)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Sep ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	3	4	8	4	1	3	2	0	0	71	26		+39.8%	24	238	597	+103.5%
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00		0.0 pt	Powerpack Viridian Therapeutics, Inc.’s next three years, line by line Analysts expect revenue to grow 103.5% a year to 2028 — faster than the 39.8% of the last 9 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(17)	(27)	(33)	(42)	(111)	(79)	(130)	(238)	(270)	(343)	(454)		+39.4%
	EBT margin, %	(496.81)	(662.30)	(389.97)	(938.65)	(10,544.29)	(2,680.16)	(7,329.23)	(75,711.46)	(89,387.09)	(483.57)	(1,724.06)		+13.2 pt
	Net income	(17)	(27)	(33)	(42)	(111)	(79)	(130)	(238)	(270)	(343)	(454)		+39.4%
Per share, $
Per share, $	Revenue	84.80	3.12	4.25	2.14	0.30	0.25	0.06	0.01	0.00	0.84	0.00		(40.2%)
	Earnings	(421.79)	(20.69)	(16.49)	(20.09)	(31.13)	(6.68)	(4.05)	(5.31)	(3.07)	(3.32)	(3.37)		(41.6%)
	Cash flow	(359.88)	(21.94)	(13.60)	(17.26)	(8.37)	(4.58)	(2.92)	(4.12)	(3.42)	(3.26)	0.00		(40.7%)
	Capex	(6.10)	(0.19)	(0.23)	(0.04)	(0.01)	(0.02)	(0.02)	(0.02)	(0.01)	(0.01)	0.00		(53.8%)
	Free cash flow	(365.98)	(22.14)	(13.82)	(17.30)	(8.38)	(4.60)	(2.95)	(4.14)	(3.43)	(3.26)	0.00		(40.8%)
	Book value	367.20	30.00	26.01	7.54	33.75	15.75	12.31	9.88	9.89	8.52	0.00		(34.2%)
	Shares, m	0	1	2	2	4	12	32	45	68	85	94		+133.6%
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.0
	P/S	0.91	49.59	10.70	3.37	30.32	79.53	516.07	3,185.59	4,309.19	37.25	117.81		822.3
	P/B	0.00	5.15	1.75	0.95	0.00	4.37	3.62	4.25	2.70	4.47	5.49		2.7
	EV/Sales	(4.62)	40.71	4.44	(0.78)	(35.56)	13.40	279.45	1,732.26	2,003.95	25.73	91.03		405.9
	EV/FCF	1.07	(5.74)	(1.36)	0.10	2.30	(0.72)	(5.23)	(2.94)	(2.60)	(6.58)	(6.97)		(2.2)
Cash, $m
Cash, $m	Operating cash flow	(15)	(28)	(27)	(36)	(30)	(55)	(94)	(184)	(232)	(276)	(342)		+38.5%
	Capex	0	0	0	0	0	0	(1)	(1)	(1)	0	(2)		+7.9%
	Free cash flow	(15)	(28)	(27)	(36)	(30)	(55)	(95)	(185)	(233)	(277)	(343)		+38.3%
Balance, $m
Balance, $m	Working capital	17	48	59	20	119	187	398	460	691	824	943		+53.9%
	Net debt	(19)	(38)	(54)	(23)	(128)	(196)	(420)	(457)	(697)	(825)	(955)		+51.8%
	Shareholders’ equity	15	39	51	16	120	188	395	442	672	722	581		+53.7%
Returns, %
Returns, %	ROA	(91.99)	(68.66)	(55.14)	(86.87)	(137.09)	(47.42)	(40.66)	(51.37)	(43.79)	(41.73)	(56.49)		+50.3 pt
	ROIC	0.00	(1,673.31)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.0 pt
	ROE	67.26	226.53	(72.79)	(124.81)	491.96	2,308.18	(84.66)	(97.35)	(75.17)	(63.87)	0.00		(131.1) pt
People
People	Employees	45	65	80	46	27	50	86	94	143	252	—		+21.1%
	Revenue/emp, $m	0.08	0.06	0.10	0.10	0.04	0.06	0.02	0.00	0.00	0.28	—		+15.4%

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 4 Nov 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
TARS Tarsus Pharmaceuticals, Inc.	$3.3B	— (loss-making)	— (loss-making)	+63.92% (above 0%: growing)	n/m	−144.14% (below 0%: shrinking)	92.86%	(340.29%)	Compare
VKTX Viking Therapeutics, Inc.	$3.3B	— (loss-making)	—	—	n/m	−47.01% (below 0%: shrinking)	0.00%	0.00%	Compare
ELVN Enliven Therapeutics, Inc.	$3.3B	— (loss-making)	—	—	n/m	−8.34% (below 0%: shrinking)	0.00%	0.00%	Compare
DYN Dyne Therapeutics, Inc.	$3.2B	— (loss-making)	—	—	n/m	−39.08% (below 0%: shrinking)	0.00%	0.00%	Compare
VRDN Viridian Therapeutics, Inc.	$3.2B	— (loss-making)	— (loss-making)	−63.51% (below 0%: shrinking)	n/m	−9.92% (below 0%: shrinking)	100.00%	(401.82%)
TLX Telix Pharmaceuticals Limited	$3.2B	—	—	—	—	−44.78% (below 0%: shrinking)	—	—	Compare
DNLI Denali Therapeutics Inc.	$3.2B	— (loss-making)	— (loss-making)	−93.96% (below 0%: shrinking)	n/m	−11.83% (below 0%: shrinking)	98.92%	(712.97%)	Compare
CELC Celcuity, Inc.	$3.1B	— (loss-making)	—	—	n/m	−53.27% (below 0%: shrinking)	0.00%	0.00%	Compare
IDYA IDEAYA Biosciences, Inc.	$3.0B	— (loss-making)	— (loss-making)	−95.07% (below 0%: shrinking)	n/m	−165.94% (below 0%: shrinking)	100.00%	(1,343.80%)	Compare
Median of peers	$3.2B	—	—	−93.96%	—	−45.89%	0.00%	0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 17 April 2026

Ownership

Directors and executive officers, together 2.40%

Entities affiliated with Fairmount Funds Management LLC 15.70%

Entities affiliated with FMR LLC 7.50%

Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Viridian Therapeutics, Inc. (VRDN) Latest News

4 Nov

Impact 4 · 8:41 PM · Moby

Viridian Therapeutics, Inc. Q3 2026 Earnings Call Summary

Impact 4 · 2:45 PM · The Motley Fool transcript

Viridian (VRDN) Q3 2026 Earnings Call Transcript

Impact 3 · 5:14 PM · MarketBeat

What Viridian Therapeutics (VRDN) Said on Its Q3 Earnings Call

Impact 3 · 7:01 AM · Business Wire

Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress

27 Oct

Impact 4 · 2:08 PM · Simply Wall St.

How FDA Approval Will Impact Viridian Therapeutics Stock

20 Oct

Impact 3 · 4:00 PM · Business Wire

Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026

16 Oct

Impact 3 · 8:12 PM · Simply Wall St.

Viridian Therapeutics (VRDN) Stock May Look Stretched Against Its Sales Base

22 Sep

Impact 3 · 11:45 AM · MT Newswires

Viridian Therapeutics' Lumvoa Off to 'Stronger Start' Than Anticipated, RBC Says

7 Aug

Impact 3 · 12:05 PM

Viridian Therapeutics to See 'Minimal' Revenue Growth in H2, RBC Capital Markets Says

6 Aug

Impact 3 · 7:01 AM

Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results

29 Jul

Impact 4 · 10:31 AM

Graves Ophthalmopathy Market Expected to Witness Rapid Expansion at a CAGR of 9% During the Forecast Period (2026-2036), Driven by the Recent Approval of Viridian's LUMVOA and the Launch of Emerging Therapies | DelveInsight

15 Jul

Impact 3 · 10:01 AM

Lumvoa’s Unique Profile Leads to Optimism Around Viridian Therapeutics (VRDN)

14 Jul

Impact 3 · 1:55 PM

“Stay Invested”: Wells Fargo Picks 2 Stocks to Buy as It Stays Bullish on the Market

6 Jul

Impact 4 · 1:21 PM

Wedbush Sees Commercial Edge for Viridian (VRDN) After FDA Milestone

30 Jun

Impact 4 · 7:33 AM · biopharmadive.com

Viridian may have edge over Amgen in eye drug showdown, analysts argue

Impact 3 · 11:53 AM

Viridian Therapeutics' Lumvoa Could Start Generating More Meaningful Revenue in 2027, RBC Says

29 Jun

Impact 5 · 7:00 AM

DRI Healthcare Comments on Viridian's FDA Approval and Launch of Lumvoa™ (veligrotug-vvze)

26 Jun

Impact 5 · 6:00 PM

Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease

Impact 4 · 6:57 PM · Stocktwits

VRDN Stock Jumps 6% After-Hours As Viridian Wins First FDA Approval

21 May

Impact 4 · 9:30 AM · Insider Monkey

Viridian Therapeutics (VRDN) Prices Upsized Concurrent Public Offerings Totaling $350M

17 May

Impact 4 · 2:52 PM · The Motley Fool

This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million

8 May

Impact 5 · 4:18 AM · Simply Wall St.

Why Viridian Therapeutics (VRDN) Is Up 25.9% After Phase 3 Elegrobart Win And Fresh Fundraising

7 May

Impact 4 · 3:41 PM · Simply Wall St.

Earnings Update: Viridian Therapeutics, Inc. (NASDAQ:VRDN) Just Reported And Analysts Are Boosting Their Estimates

6 May

Impact 5 · 8:13 AM · clinicaltrialsarena.com

Viridian Therapeutics’ stock up 35% after Phase III TED data release

Impact 5 · 4:24 AM · MarketBeat

Viridian Therapeutics REVEAL-2 Hits Phase 3 Endpoint, Shows “IV-like” Proptosis Gains in Chronic TED

Impact 4 · 11:13 PM · Business Wire

Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million

5 May

Impact 4 · 9:50 PM · Insider Monkey

Viridian (VRDN) Climbs 33% on Looming Drug Commercialization

Impact 4 · 4:24 PM · Investor's Business Daily

How This Amgen Rival, Up 33%, Plans To Shake Its Grip In Thyroid Eye Disease

Impact 4 · 4:05 PM · Business Wire

Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock

Impact 4 · 10:24 AM · InvestorsHub

PDUFA Decision Nears as Viridian Therapeutics (VRDN) Advances TED Pipeline and Reports Q1 Results

Viridian Therapeutics, Inc.

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Viridian Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 17 April 2026

Ownership

Viridian Therapeutics, Inc. (VRDN) Latest News

4 Nov

27 Oct

20 Oct

16 Oct

22 Sep

7 Aug

6 Aug

29 Jul

15 Jul

14 Jul

6 Jul

30 Jun

29 Jun

26 Jun

21 May

17 May

8 May

7 May

6 May

5 May

VRDN metrics, ten years each

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Viridian Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 17 April 2026

Ownership

Viridian Therapeutics, Inc. (VRDN) Latest News

4 Nov

27 Oct

20 Oct

16 Oct

22 Sep

7 Aug

6 Aug

29 Jul

15 Jul

14 Jul

6 Jul

30 Jun

29 Jun

26 Jun

21 May

17 May

8 May

7 May

6 May

5 May

VRDN metrics, ten years each

Stockrow Weekly